Can-Fite plans to discuss possible licensing, drug-development, and sales partnerships at BIO-Europe. The report names no signed deal or new trial result, so it does not change the company's outlook.
These discussions could create ways to develop or sell Can-Fite’s drug candidates, but the company has only said it will seek talks. The report names no signed deal or new trial result, so its outlook stays unchanged.
Follow Can-Fite BioPharma (CANF) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CANF